Peptron, Inc.
KOSDAQ 087010.KQ
Peptron, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -34.08%
Peptron, Inc. Return on Capital Employed (ROCE) is -34.08% for the year ending December 31, 2023, a -32.53% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
-
Peptron, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -25.72%, a -20.20% change year over year.
-
Peptron, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -21.39%, a -8.29% change year over year.
-
Peptron, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -19.76%, a 6.91% change year over year.
-
Peptron, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -21.22%, a -84.69% change year over year.
Key data
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Market news
Loading...
KOSDAQ: 087010.KQ
| CEO | Mr. Ho-Il Choi |
| IPO Date | July 22, 2015 |
| Location | South Korea |
| Headquarters | 37-24, Yuseong-daero 1628 beon-gil |
| Employees | 94 |
| Sector | Health Care |
| Industries | |
Description
Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email